Volume Alert - GILD 100.39 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:07 AM

Volume Alert - GILD 100.39 Gilead Sciences $GILD Hit a high today of 103.79 Closing the day 10:30 at 100.39 -3.81 -3.66% With a day low of 100.06 and a total volume of 8,270,259.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Early Glance: Biotechnology companies
AP - 19 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 101.28 (-2.92), AMGN: 158.21 (-2.64), CELG: 103.40 (-4.03)

Gilead Sciences (GILD) Crosses Pivot Point Support at $102.79
Comtex SmarTrend(R) - 1 hr 9 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $104.92 and have already reached the first level of support at $102.79. Investors may be interested in a cross of the next downside pivot targets of $101.38 and $97.84.
GILD: 101.28 (-2.92)

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - 1 hr 43 mins ago
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 101.28 (-2.92), AMGN: 158.21 (-2.64), SNY: 46.49 (-0.04), REGN: 400.16 (-2.47)

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - 1 hr 56 mins ago
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.28 (-2.92), IBIO: 1.10 (+0.02), ARIA: 6.18 (-0.07), MNKD: 6.23 (+0.05), CELG: 103.40 (-4.03)

Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
PR Newswire - 2 hrs 21 mins ago
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: BlackBerry (NASDAQ:BBRY), Twitter (NYSE:TWTR), Alibaba (NYSE:BABA), Sirius XM (NASDAQ:SIRI), Gilead Sciences (NASDAQ:GILD), and JD.Com (NASDAQ:JD).
GILD: 101.28 (-2.92), BBRY: 11.63 (-0.43), JD: 26.45 (-0.87), TWTR: 40.69 (+0.65), SIRI: 3.52 (+0.01), BABA: 114.69 (-0.15)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.59 (-0.48), GILD: 101.28 (-2.92), MRK: 58.97 (-0.57), ABBV: 63.44 (-0.19)

If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST

GILD: 101.28 (-2.92), ABBV: 63.44 (-0.19)

Most active Nasdaq-traded stocks
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
GILD: 101.28 (-2.92), FB: 74.57 (+0.32), CMCSK: 54.05 (+0.02), ZNGA: 2.71 (-0.02), MSFT: 49.93 (+0.32), INTC: 33.87 (+0.19), GRPN: 7.79 (+0.02), CMCSA: 54.21 (-0.09), AAPL: 113.95 (+1.13), SUSQ: 13.12 (+0.06), CSCO: 26.05 (+0.37)

Final Glance: Biotechnology companies
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.28 (-2.92), AMGN: 158.21 (-2.64), CELG: 103.40 (-4.03)

Midday Glance: Biotechnology companies
AP - Thu Nov 13, 12:28PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 101.28 (-2.92), AMGN: 158.21 (-2.64), CELG: 103.40 (-4.03)

Gilead prices debt offering
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:19AM CST

GILD: 101.28 (-2.92)

Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:44AM CST
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 101.28 (-2.92)

Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 101.28 (-2.92)

Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 101.28 (-2.92)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.30 (+1.09), JNJ: 108.59 (-0.48), GILD: 101.28 (-2.92), ABBV: 63.44 (-0.19)

Gilead Sciences Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 101.28 (-2.92)

Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 101.28 (-2.92)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 101.28 (-2.92), ABBV: 63.44 (-0.19)

Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST

GILD: 101.28 (-2.92), MRK: 58.97 (-0.57)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOCaaS Market Grows to $16.68B by 2031, What It Means

SOC as a Service: More Than Just Jargon The term 'SOC as a Service' (SOCaaS) might sound like some alphabet soup, but it’s a serious contender in today’s digital security world. With projected growth from $9.04 billion in 2026 to a whopping $16.68 billion by 2031, the SOCaaS market isn’t just having a moment, it’s setting up a stage for the long haul. It’s like...

Leviton Ignites Bridgestone Arena's Modern Makeover

A Power Play in Technology: Leviton's Big Move Forget your lazy Sunday strolls, the latest buzz is all about connectivity at sports arenas. Leviton, the century-old stalwart in networking and electrical solutions, has just tied the knot with the Nashville Predators to electrify Bridgestone Arena. This ain't just a handshake deal; it's a calculated step to transform how...

Supercar Buying: Key Factors to Verify First

The Grind of Securing a Limited-Edition Supercar If you're grinding to buy one of those elusive limited-edition supercars, you'd better buckle up. According to Kendall Gath over at iLusso, this ain't like picking up groceries at the local market. There's a whole list of things to consider before you even think about handing over your wad of cash. Differentiating Fact from...

CASEKOO's Spooky Collectibles: Postcards Meet Cases

Here we go with an unexpected twist in the phone accessory game. CASEKOO decided it's time to mix things up this Halloween with something as peculiar as it is intriguing: limited-edition Spooky Season Commemorative Postcards. A Spooky Strategy to Celebrate Ten Years Get this, folks—CASEKOO's looking to mark a decade in the business with more than just confetti and a...

Podcast Giants Converge in Tennessee for POD U Summit

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Patrick Ta Beauty Adds New Leadership to Expand Growth

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Violet PR's Big Wins Hint at Industry Strategies

A Shining Night in Morristown Picture Violet PR's team on top of the world, right there in Morristown, getting the accolades every agency dreams of—five awards from PRSA-NJ. It's not just an ego trip, either. This is about setting a high bar in the world of strategic communications, and they're flaunting their ability to drive growth and innovation in the economic...

Gentex Shares Tumble Amid Legal Investigation Concerns

Gentex's Financial Outlook Takes a Hit Well, here we are again, catching another corporate hiccup. Gentex Corporation, or as ticker hounds know it, NASDAQ:GNTX, just pulled the rug out from its investors by chopping the top off its 2026 revenue guidance. Dropping to a floor it once considered a ceiling, $2.65 billion is now the most optimistic number they're pitching. No...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...